Devyser achieves breakthrough in the US with cystic fibrosis NGS test
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Devyser has secured a CFTR NGS proposal with UNC Hospitals. The proposal with UNC Hospitals is valid for a period of up to four years. Indicative order value is estimated to be approximately 2.5 million SEK annually.
"Devyser CFTR NGS is one of the few products that meet the newly implemented ACMG recommendations. This is the first deal secured for Devyser CFTR NGS in the US, and I am very proud of the entire team who made this happen. We are also very optimistic for the future of Devyser CFTR NGS, especially in the US, where we see a lot of interest," said CEO Fredrik Alpsten. "This proposal is another confirmation of the competitiveness of our high quality and simple CFTR NGS solution."
In 2023, ACMG (the American College of Medical Genetics and Genomics) updated its recommendations regarding the number of screening variants, from 23 to 100. Devyser CFTR NGS captures all cystic fibrosis gene (CFTR) mutations, including the 100 from the ACMG recommendations, in a single assay that is designed for fast and efficient lab processing.
Cystic fibrosis is a progressive, genetic disease that affects the lungs, pancreas, and other organs. Approximately 1.4 million cystic fibrosis genetic tests are performed each year in the US [1].
Devyser CFTR NGS is for Research Use Only (USA and Canada). Not for use in diagnostic procedures.
[1] Lyon E, Schrijver I, Weck KE, Ferreira-Gonzalez A, Richards CS, Palomaki GE; CAP/ACMG Biochemical and Molecular Genetics Committee. Molecular genetic testing for cystic fibrosis: laboratory performance on the College of American Pathologists external proficiency surveys. Genet Med. 2015 Mar;17(3):219-25. doi: 10.1038/gim.2014.93. Epub 2014 Jul 31. PMID: 25077647.